DE60011678D1 - Depsipeptide und deren analoge zur verwendung als immunosuppressiva - Google Patents

Depsipeptide und deren analoge zur verwendung als immunosuppressiva

Info

Publication number
DE60011678D1
DE60011678D1 DE60011678T DE60011678T DE60011678D1 DE 60011678 D1 DE60011678 D1 DE 60011678D1 DE 60011678 T DE60011678 T DE 60011678T DE 60011678 T DE60011678 T DE 60011678T DE 60011678 D1 DE60011678 D1 DE 60011678D1
Authority
DE
Germany
Prior art keywords
depsipeptides
grant
immunosuppressiva
analogs
suffering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60011678T
Other languages
English (en)
Other versions
DE60011678T2 (de
Inventor
The Panum Institute Skov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xcyte Therapies Inc
Original Assignee
Xcyte Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26865325&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60011678(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Xcyte Therapies Inc filed Critical Xcyte Therapies Inc
Publication of DE60011678D1 publication Critical patent/DE60011678D1/de
Application granted granted Critical
Publication of DE60011678T2 publication Critical patent/DE60011678T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60011678T 1999-12-08 2000-12-06 Depsipeptide und deren analoge zur verwendung als immunosuppressiva Expired - Lifetime DE60011678T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16973199P 1999-12-08 1999-12-08
US169731P 1999-12-08
US19358200P 2000-03-30 2000-03-30
US193582P 2000-03-30
PCT/US2000/033169 WO2001042282A1 (en) 1999-12-08 2000-12-06 Depsipeptide and congeners thereof for use as immunosuppressants

Publications (2)

Publication Number Publication Date
DE60011678D1 true DE60011678D1 (de) 2004-07-22
DE60011678T2 DE60011678T2 (de) 2005-07-14

Family

ID=26865325

Family Applications (3)

Application Number Title Priority Date Filing Date
DE60033453T Expired - Lifetime DE60033453T2 (de) 1999-12-08 2000-12-06 Verwendung von Depsipeptide und deren Analoge als Immunosuppressiva zur Behandlung von Infektionskrankheiten, Autoimmunerkrankungen, Allergien und hyperproliferativer Hautkrankheiten
DE60044542T Expired - Lifetime DE60044542D1 (de) 1999-12-08 2000-12-06 Depsipetid und Kongenere davon für den Einsatz als Immunsuppressiva zur Vorbeugung und Behandlung von Abstossreaktionen infolge einer Transplantation und zur Induktion des Apoptosis in aktivierten CD4 oder CD8 T-Zellen
DE60011678T Expired - Lifetime DE60011678T2 (de) 1999-12-08 2000-12-06 Depsipeptide und deren analoge zur verwendung als immunosuppressiva

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DE60033453T Expired - Lifetime DE60033453T2 (de) 1999-12-08 2000-12-06 Verwendung von Depsipeptide und deren Analoge als Immunosuppressiva zur Behandlung von Infektionskrankheiten, Autoimmunerkrankungen, Allergien und hyperproliferativer Hautkrankheiten
DE60044542T Expired - Lifetime DE60044542D1 (de) 1999-12-08 2000-12-06 Depsipetid und Kongenere davon für den Einsatz als Immunsuppressiva zur Vorbeugung und Behandlung von Abstossreaktionen infolge einer Transplantation und zur Induktion des Apoptosis in aktivierten CD4 oder CD8 T-Zellen

Country Status (16)

Country Link
US (2) US6403555B1 (de)
EP (3) EP1438966B1 (de)
JP (4) JP4824890B2 (de)
KR (1) KR20020062956A (de)
CN (1) CN1414971A (de)
AT (3) ATE470447T1 (de)
AU (1) AU762525B2 (de)
BR (1) BR0016154A (de)
CA (1) CA2393682C (de)
DE (3) DE60033453T2 (de)
DK (1) DK1438966T3 (de)
ES (3) ES2282751T3 (de)
HK (2) HK1049849B (de)
IL (2) IL149995A0 (de)
PT (1) PT1438966E (de)
WO (1) WO2001042282A1 (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6822267B1 (en) * 1997-08-20 2004-11-23 Advantest Corporation Signal transmission circuit, CMOS semiconductor device, and circuit board
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US8119159B2 (en) 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
EP1313872A1 (de) * 2000-09-01 2003-05-28 Fujisawa Pharmaceutical Co., Ltd. Verfahren zur herstellung von fr901228
AU2002243231A1 (en) * 2000-11-21 2002-07-24 Wake Forest University Method of treating autoimmune diseases
US6632553B2 (en) * 2001-03-27 2003-10-14 Mti Microfuel Cells, Inc. Methods and apparatuses for managing effluent products in a fuel cell system
JP4238728B2 (ja) * 2001-08-21 2009-03-18 アステラス製薬株式会社 ヒストンデアセチラーゼ阻害剤の医薬用途ならびにその抗腫瘍効果の評価方法
US8846039B2 (en) * 2002-04-26 2014-09-30 Asan Laboratories Company (Cayman), Limited Method for ameliorating pruritus
US8946295B2 (en) * 2002-07-25 2015-02-03 Sunny Pharmtech Inc. Histone hyperacetylating agents for promoting wound healing and preventing scar formation
US8163764B2 (en) * 2002-04-26 2012-04-24 Asan Laboratories Company (Cayman) Limited Skincare methods
US20060275370A1 (en) * 2002-07-25 2006-12-07 Yih-Lin Chung Method and compositions for treatment of epithelial damage
US8883148B2 (en) * 2002-04-26 2014-11-11 Asan Laboratories Company (Cayman), Limited Prevention of joint destruction
US6809118B2 (en) * 2002-07-25 2004-10-26 Yih-Lin Chung Methods for therapy of radiation cutaneous syndrome
CA2495354A1 (en) * 2002-08-20 2004-03-04 Yamanouchi Pharmaceutical Co., Ltd. An agent for inhibiting articular cartilage extracellular matrix degradation
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
CA2518318A1 (en) 2003-03-17 2004-09-30 Takeda San Diego, Inc. Histone deacetylase inhibitors
DE602004027244D1 (de) * 2003-06-27 2010-07-01 Astellas Pharma Inc Therapeutisches mittel für ein weichteilsarkom
WO2005007109A2 (en) * 2003-07-09 2005-01-27 Henry Ford Health System Methods and compositions for cancer therapy using a novel adenovirus
WO2005030239A2 (en) * 2003-09-25 2005-04-07 Astellas Pharma Inc. Antitumor agent comprising a histone deacetylase inhibitor and a topoisomerase ii inhibitor
US20050159470A1 (en) * 2003-12-19 2005-07-21 Syrrx, Inc. Histone deacetylase inhibitors
WO2005066151A2 (en) * 2003-12-19 2005-07-21 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20050187148A1 (en) * 2004-02-25 2005-08-25 Yoshinori Naoe Antitumor agent
US7951780B2 (en) * 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
EP1812036A2 (de) * 2004-11-17 2007-08-01 The University Of Chicago Histon-deacetylase-hemmer und anwendungsverfahren
EP1824831A2 (de) 2004-12-16 2007-08-29 Takeda San Diego, Inc. Histondeacetylase-inhibitoren
JP2008540574A (ja) 2005-05-11 2008-11-20 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
GB0511266D0 (en) 2005-06-02 2005-07-13 Trust Chemical compounds
CA2615105A1 (en) * 2005-07-14 2007-01-25 Takeda San Diego, Inc. Histone deacetylase inhibitors
JP2009507081A (ja) * 2005-09-07 2009-02-19 ブレインセルス，インコーポレイティド ＨＤａｃ阻害による神経発生の調整
CA2630216A1 (en) * 2005-11-18 2007-05-31 Gloucester Pharmaceuticals, Inc. Metabolite derivatives of the hdac inhibitor fk228
EP1976835A2 (de) * 2006-01-13 2008-10-08 Takeda San Diego, Inc. Histondeacetylase-inhibitoren
ES2426445T3 (es) 2006-04-07 2013-10-23 Merrion Research Iii Limited Forma de dosificación oral sólida que contiene un potenciador
EP2012801A4 (de) 2006-04-24 2009-08-05 Gloucester Pharmaceuticals Inc Gemcitabin-kombinationstherapie
WO2007146730A2 (en) 2006-06-08 2007-12-21 Gloucester Pharmaceuticals Deacetylase inhibitor therapy
CA2654566A1 (en) * 2006-06-09 2007-12-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US7883855B2 (en) 2006-07-21 2011-02-08 Abbott Laboratories Immunosuppressant drug extraction reagent for immunoassays
CA2670223A1 (en) * 2006-11-22 2008-05-29 Karus Therapeutics Limited Depsipeptides and their therapeutic use
GB0623388D0 (en) * 2006-11-23 2007-01-03 Univ Southampton Chemical compounds
US7914999B2 (en) 2006-12-29 2011-03-29 Abbott Laboratories Non-denaturing lysis reagent
EP2450049A1 (de) * 2006-12-29 2012-05-09 Gloucester Pharmaceuticals, Inc. Tumorbehandlung auf der basis von romidepsin
CA2674309A1 (en) 2006-12-29 2008-07-10 Gloucester Pharmaceuticals, Inc. Preparation of romidepsin
US8795627B2 (en) 2007-03-21 2014-08-05 Raptor Pharmaceuticals Inc. Treatment of liver disorders by administration of RAP conjugates
WO2008151306A1 (en) * 2007-06-05 2008-12-11 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Synthesis of cyclodepsipeptide compounds having antineoplastic and/or antimicrobial activity
GB0715750D0 (en) * 2007-08-13 2007-09-19 Karus Therapeutics Ltd Chemical compounds
CA2709272C (en) * 2007-12-19 2015-03-10 Abbott Laboratories Immunosuppressant drug extraction reagent for immunoassays
US8999383B2 (en) 2008-05-07 2015-04-07 Merrion Research Iii Limited Compositions of GnRH related compounds and processes of preparation
CA2725278A1 (en) * 2008-05-22 2009-11-26 Karus Therapeutics Limited Depsipeptides and their therapeutic use
EP2293845A1 (de) * 2008-05-22 2011-03-16 Karus Therapeutics Limited Depsipeptide und ihre therapeutische verwendung
CA2763299C (en) * 2009-06-26 2015-11-24 Asan Laboratories Co., Ltd. Method for treating or ameliorating mucocutaneous or ocular toxicities
TWI412359B (zh) * 2009-07-07 2013-10-21 Asan Lab Co Ltd 組織蛋白去乙醯酵素抑制劑在製備治療或減緩黏膜／皮膚或眼睛毒性或副作用之藥物的用途
US9089484B2 (en) 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
CN103108648A (zh) 2010-07-12 2013-05-15 细胞基因公司 罗米地辛固体形式及其用途
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
WO2012094598A2 (en) 2011-01-07 2012-07-12 Merrion Research Iii Limited Pharmaceutical compositions of iron for oral administration
JP6214397B2 (ja) * 2011-09-30 2017-10-18 国立大学法人東北大学 新規ホスファチジルイノシトール３キナーゼ阻害剤及び医薬組成物
JP6492003B2 (ja) 2012-03-30 2019-03-27 ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ 発作を減少させるためおよび神経変性症候群を改質するためにタウ発現を調節する方法
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
TW202246503A (zh) 2013-07-19 2022-12-01 美商百健Ｍａ公司 用於調節τ蛋白表現之組合物
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
KR20150140177A (ko) * 2014-06-05 2015-12-15 한미약품 주식회사 단백질 및 펩타이드의 면역원성을 감소시키는 방법
US10265384B2 (en) 2015-01-29 2019-04-23 Novo Nordisk A/S Tablets comprising GLP-1 agonist and enteric coating
CN110760564A (zh) * 2019-10-16 2020-02-07 菲诺克生物科技(上海)有限公司 细胞周期检测方法及其所用试剂与试剂盒

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4268516A (en) 1978-10-11 1981-05-19 Pfizer Inc. [1]Benzothiopyrano[4,3-c]pyrazoles as immunoregulatory agents
US4950649A (en) * 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
GB8817743D0 (en) * 1988-07-26 1988-09-01 Fujisawa Pharmaceutical Co Fr901228 substance & preparation thereof
AU3972193A (en) 1992-04-07 1993-11-08 Scripps Research Institute, The Method for inducing tolerance to an antigen using butyrate
ZA946765B (en) 1993-09-02 1996-02-15 Dartmouth College Methods of prolonged suppression of humoral immunity
US5591717A (en) 1994-04-06 1997-01-07 Rojko; Jennifer L. Branched apogenic peptide for inducing apoptosis
WO1995033823A1 (en) 1994-06-03 1995-12-14 The United States Of America, Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of t cells
US5843943A (en) 1994-12-29 1998-12-01 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
US5962019A (en) 1995-08-25 1999-10-05 Sangstat Medical Corporation Oral cyclosporin formulations
US5891653A (en) 1995-12-29 1999-04-06 Attfield; Derrick Cecil Method of suppressing graft rejection by means of stress proteins
US6777217B1 (en) * 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
EP0972012A4 (de) 1997-03-03 2004-09-29 Univ Duke Immunsuppression
DE19713626A1 (de) * 1997-04-02 1998-10-08 Bayer Ag Neue Thiodepsipeptide zur Bekämpfung von Endoparasiten und ein einfaches Verfahren zu ihrer Herstellung
WO1998046640A2 (en) 1997-04-15 1998-10-22 Coulter International Corp. Methods and compositions for inducing immunosuppression
EP1010705A4 (de) 1997-09-02 2004-09-15 Sumitomo Pharma Neuartige zyklische tetrapeptidderivate und deren medizinische verwendung
AU9395998A (en) 1997-09-17 1999-04-05 Genentech Inc. Compositions and methods for the treatment of immune related diseases
AU9398398A (en) 1997-09-22 1999-04-12 Sloan-Kettering Institute For Cancer Research Reverse prenyl compounds as immunosuppressants
WO1999025703A1 (en) 1997-11-14 1999-05-27 Merck & Co., Inc. Immunosuppressant tetracyclic triterpenes
AU1864999A (en) 1997-12-15 1999-07-05 Universite Laval Methods and compositions for improving the success of cell transplantation in a host
JPH11180873A (ja) 1997-12-22 1999-07-06 Kaken Shoyaku Kk ＮＦ−κＢ活性阻害剤
US6001815A (en) * 1997-12-25 1999-12-14 Nisshin Flour Milling Co., Ltd. Depsipeptides containing N-substituted glycine residue
US6211145B1 (en) * 1997-12-25 2001-04-03 Nisshin Flour Milling Co., Ltd. Bicyclic depsipeptides
EP0931792B1 (de) * 1998-01-27 2004-01-07 Nisshin Seifun Group Inc. Depsipeptide, die nicht-natürliche Aminosäuren enthalten
US6287843B1 (en) 1998-04-03 2001-09-11 Pioneer Hi-Bred International, Inc. Maize histone deacetylases and their use
KR100611265B1 (ko) * 1999-01-13 2006-08-10 아스텔라스세이야쿠 가부시키가이샤 신규 뎁시펩티드 화합물

Also Published As

Publication number Publication date
PT1438966E (pt) 2007-05-31
EP1438966A2 (de) 2004-07-21
EP1438966B1 (de) 2007-02-14
ES2282751T3 (es) 2007-10-16
HK1049849A1 (en) 2003-05-30
KR20020062956A (ko) 2002-07-31
EP1779859A3 (de) 2007-05-16
WO2001042282A9 (en) 2002-05-30
DE60044542D1 (de) 2010-07-22
JP2013107902A (ja) 2013-06-06
HK1070268A1 (en) 2005-06-17
US20020045575A1 (en) 2002-04-18
AU2068001A (en) 2001-06-18
AU762525B2 (en) 2003-06-26
ATE353663T1 (de) 2007-03-15
JP2003516418A (ja) 2003-05-13
IL149995A (en) 2009-09-01
DE60033453D1 (de) 2007-03-29
JP4824890B2 (ja) 2011-11-30
EP1246839A1 (de) 2002-10-09
CN1414971A (zh) 2003-04-30
US6403555B1 (en) 2002-06-11
JP2011084585A (ja) 2011-04-28
JP2014205714A (ja) 2014-10-30
EP1779859A2 (de) 2007-05-02
ES2225282T3 (es) 2005-03-16
ATE269354T1 (de) 2004-07-15
WO2001042282A1 (en) 2001-06-14
DK1438966T3 (da) 2007-06-11
EP1779859B1 (de) 2010-06-09
ES2347284T3 (es) 2010-10-27
IL149995A0 (en) 2002-12-01
BR0016154A (pt) 2003-02-25
CA2393682C (en) 2012-01-31
ATE470447T1 (de) 2010-06-15
EP1246839B1 (de) 2004-06-16
CA2393682A1 (en) 2001-06-14
EP1438966A3 (de) 2004-08-04
US6548479B1 (en) 2003-04-15
HK1049849B (zh) 2004-12-03
DE60011678T2 (de) 2005-07-14
DE60033453T2 (de) 2007-11-29

Similar Documents

Publication Publication Date Title
DE60011678D1 (de) Depsipeptide und deren analoge zur verwendung als immunosuppressiva
EP2418220A3 (de) Interferon-Alpha-Antikörper und deren Verwendungen
CY1116107T1 (el) Ενωσεις για χρηση στην αγωγη αυτοανοσων παθησεων, ανοσο-αλλεργικων παθησεων και απορριψης μεταμοσχευσης οργανων ή ιστων
UA49869C2 (uk) Нафтил-заміщені похідні бензимідазолу, фармацевтична композиція, спосіб лікування (варіанти) та спосіб інгібування людського фактора
ATE444960T1 (de) Polyhydroxystilbene und -stilbenoxide als antipsoriasismittel und proteinkinasehemmer
ES2099158T3 (es) Tratamiento del rechazo de trasplantes o de enfermedades autoinmunitarias y complejo de la formula general x-pro-y-boropro asociada al mismo.
DE69333775D1 (de) Synthetische katalytische freie radikalfänger, verwendbar als antioxidantien zur prävention und therapie von krankheiten
UA86344C2 (ru) Способ лечения сосудистых заболеваний
DK1151009T3 (da) Antimikrobielt/endotoksin-neutraliserende polypeptid
DE60231522D1 (de) Behandlung und vorbeugung von insulin-produzierende zelltransplantatabstossung
BG104091A (en) Cd154 blockade therapty in tissue transplantation of pancreatic isles
DE602005016729D1 (de) Verwendung von 5'-methylthioadenosin zur prävention und/oder behandlung von autoimmunkrankheiten und/oder transplantatabstossung
HK1010340A1 (en) The manufacture of compositions for the treatment of cell proliferation disorders
PL324424A1 (en) Therapeutic factors and autoimmunological diseases
EE04261B1 (et) Aminoadamantaaniühendite kasutamine immunoregulaatoritena
ATE410172T1 (de) Verwendung eines analoges des vitamins d3 zur behandlung des autoimmunen diabetes
MXPA00010254A (es) Tratamiento de disfuncion sexual en ciertos grupos de pacientes.
ATE546154T1 (de) Anti-angiogenetisches mittel und seine verwendung bei der krebsbehandlung
WO2003001877A3 (en) Methods for the diagnosis and treatment of cardiac tissue rejection
NO20022109D0 (no) Anvendelse av treosulfan for behandling av pasienter för benmargs- eller blodstamcelletansplantasjon
DE69731284D1 (de) Verwendung Von Coxiella Bakterien zur Behandlung von Autoimmunkrankheiten
DE69915849D1 (de) Verwendung von gnrh analogen zur behandlung von schizophrenie
ATE283063T1 (de) Allogene und xenogene transplantation
MX9606031A (es) Inhibidores de cetona perfluoroalquilica de elastasa y procesos para fabricarlos.

Legal Events

Date Code Title Description
8363 Opposition against the patent